2 results
Not approvedWill not start
To induce a vaccine specific immune response, hereby we hope to introduce the possibility of a new treatment to improve patient outcome and survival.
Approved WMOCompleted
-To dertermine the objective response rate (ORR) and disease control rate (DCR) (according to RECIST v1.1) after 3 months of treatment with T-DM1 and osimertinib in patients with EGFR mutation positive NSCLC and HER2 bypass track activation-To…